Apotex 2nd biosimilar under FDA review; seeks filgrastim OK
This article was originally published in Scrip
Executive Summary
The FDA is reviewing a second biosimilar application from Canadian drug maker Apotex – this time a version of Amgen's Neupogen (filgrastim), which made about $1bn in sales last year.
You may also be interested in...
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
The FDA's rejection of Sandoz Inc.'s version of Amgen's Neulasta (pegfilgrastim) has revealed the hard truth that chasing the biosimilar market may be a riskier and more costly endeavor than companies anticipated.
Sandoz's Biosimilar Rejection Ups Risks, But Won't Kill Market
The FDA's rejection of Sandoz Inc.'s version of Amgen's Neulasta (pegfilgrastim) has revealed the hard truth that chasing the biosimilar market may be a riskier and more costly endeavor than companies anticipated.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.